Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2019 Filed Aug 30, 2019 21:20 UTC |
Pavliv LeoSVP and Chief Development Off.
|
Tax withholdingCommon Stock | 1,850 | $5.63 | $10,415.50 |
DisclosureSEC source: 0001209191-19-047852 · doc4.xml · nonDerivative · entry 1 Pavliv Leo · CIK 0001408593 · SVP and Chief Development Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,761 F1 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| August 26, 2019 Filed Aug 30, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,400 | $5.16 | $7,224.00 |
DisclosureSEC source: 0001209191-19-047851 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,731 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.07, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.15, inclusive. Read SEC document |
| August 26, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.14 | $385.50 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 11 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,379 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 23, 2019 Filed Aug 30, 2019 21:18 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 500 | $5.33 | $2,665.00 |
DisclosureSEC source: 0001209191-19-047851 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,131 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.07, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.30, inclusive. Read SEC document |
| August 23, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.38 | $322.80 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 18 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,498 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 23, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.38 | $349.70 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,052 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 23, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.38 | $322.80 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 18 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,422 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 22, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.31 | $318.60 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 17 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 22, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.31 | $345.15 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,987 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 22, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.31 | $318.60 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 17 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,362 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:56 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,100 | $5.45 | $11,445.00 |
DisclosureSEC source: 0001209191-19-047327 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,631 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| August 21, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.49 | $329.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 16 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,378 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 21, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.49 | $356.85 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,922 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 21, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.49 | $329.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 16 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,302 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 21, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.39 | $404.25 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 10 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,304 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 20, 2019 Filed Aug 23, 2019 20:56 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,631 | $5.41 | $14,233.71 |
DisclosureSEC source: 0001209191-19-047327 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,731 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.38, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.38, inclusive. Read SEC document |
| August 20, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.43 | $325.80 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 15 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,318 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 20, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.43 | $352.95 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,857 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 20, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.43 | $325.80 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 15 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,242 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 19, 2019 Filed Aug 23, 2019 20:56 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,000 | $5.45 | $5,450.00 |
DisclosureSEC source: 0001209191-19-047327 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,362 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| August 19, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.51 | $330.60 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 14 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,258 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 19, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.51 | $358.15 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,792 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 19, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.51 | $330.60 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 14 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,182 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 16, 2019 Filed Aug 23, 2019 20:56 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 500 | $5.71 | $2,855.00 |
DisclosureSEC source: 0001209191-19-047327 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,362 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.38, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.69, inclusive. Read SEC document |
| August 16, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $5.62 | $674.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 13 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,198 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 16, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $5.62 | $730.60 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 13 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,727 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 16, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $5.62 | $674.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 13 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,122 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 16, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.52 | $414.00 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 9 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,229 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 15, 2019 Filed Aug 23, 2019 20:56 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 78 | $5.75 | $448.50 |
DisclosureSEC source: 0001209191-19-047327 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,862 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. Read SEC document |
| August 14, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.49 | $329.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 12 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,078 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 14, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.49 | $356.85 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 12 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,597 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 14, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.49 | $329.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 12 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765,002 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 13, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,300 | $5.75 | $7,475.00 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 8 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,940 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F10 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.76 to $5.75, inclusive. Read SEC document |
| August 13, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.78 | $346.80 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 11 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,018 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 13, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.78 | $375.70 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 11 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,532 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 13, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.78 | $346.80 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 11 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,942 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 13, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.63 | $422.25 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 8 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,154 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 12, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 900 | $5.75 | $5,175.00 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 7 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,240 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F9 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.75, inclusive. Read SEC document |
| August 12, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.91 | $354.60 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 10 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,958 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 12, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.91 | $384.15 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 10 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,467 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 12, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.91 | $354.60 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 10 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,882 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 09, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 188 | $5.79 | $1,088.52 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 6 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,140 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F8 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.76, inclusive. Read SEC document |
| August 09, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 120 | $6.02 | $722.40 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 9 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,898 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 09, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 130 | $6.02 | $782.60 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 9 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,402 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 09, 2019 Filed Sep 20, 2019 21:16 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 120 | $6.02 | $722.40 |
DisclosureSEC source: 0001209191-19-050360 · doc4.xml · nonDerivative · entry 9 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,764,822 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 08, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 502 | $6.01 | $3,017.02 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,328 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F7 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.08 to $5.95, inclusive. Read SEC document |
| August 08, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.98 | $448.50 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 7 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,079 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 07, 2019 Filed Aug 16, 2019 21:11 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 700 | $5.98 | $4,186.00 |
DisclosureSEC source: 0001209191-19-046347 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,830 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.75, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.04 to $5.95, inclusive. Read SEC document |
| August 07, 2019 Filed Sep 20, 2019 21:17 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.07 | $364.20 |
DisclosureSEC source: 0001209191-19-050362 · doc4.xml · nonDerivative · entry 8 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,778 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| August 07, 2019 Filed Sep 20, 2019 21:18 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.07 | $394.55 |
DisclosureSEC source: 0001209191-19-050363 · doc4.xml · nonDerivative · entry 8 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,272 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.